[1]
|
Carrell, R.W. and Lomas, D.A. (1997) Conformational Disease. Lancet, 350, 134-138. https://doi.org/10.1016/S0140-6736(97)02073-4
|
[2]
|
Carrell, R.W. and Gooptu, B. (1998) Conformational Changes and Disease-Serpins, Prions and Alzheimer’s. Current Opinion in Structural Biology, 8, 799-809.
https://doi.org/10.1016/S0959-440X(98)80101-2
|
[3]
|
Soto, C. (2003) Unfolding the Role of Protein Misfolding in Neurodegenerative Diseases. Nature Reviews Neuroscience, 4, 49-60. https://doi.org/10.1038/nrn1007
|
[4]
|
Sipe, J.D., Benson, M.D., Buxbaum, J.N., Ikeda, S-I., Merlini, G., Saraiva, J.M. and Westermark, P. (2014) Nomenclature 2014: Amyloid Fibril Proteins and Clinical Classification of the Amyloidosis. Amyloid, 21, 221-224.
https://doi.org/10.3109/13506129.2014.964858
|
[5]
|
Lomas, D.A. and Carrell, R.W. (2002) Serpinopathies and the Conformational Dementias. Nature Reviews Genetics, 3, 759-768. https://doi.org/10.1038/nrg907
|
[6]
|
Mahadeva, R. and Lomas, D.A. (1998) α1-Antitrypsin Deficiency, Cirrhosis and Emphysema. Thorax, 53, 501-505. https://doi.org/10.1136/thx.53.6.501
|
[7]
|
Potempa, J., Korzus, E. and Travis, J. (1994) The Serpin Superfamily of Proteinase Inhibitors: Structure, Function and Regulation. Journal of Biological Chemistry, 269, 15957-15960.
|
[8]
|
Breydo, L., Wu, J.W. and Uversky, V.N. (2012) α-Synuclein Misfolding and Parkinson Disease. BBA, 1822, 261-285.
|
[9]
|
Stefani, M. and Dobson, C.M. (2003) Protein Aggregation and Aggregate Toxicity: New Insights into Protein Folding, Misfolding Diseases and Biological Evolution. Journal of Molecular Medicine, 81, 678-699.
https://doi.org/10.1007/s00109-003-0464-5
|
[10]
|
Mandelkow, E.-M. and Mandelkow, E. (2012) Biochemistry and Cell Biology of Tau Protein in Neurofibrillar Degeneration. Cold Spring Harbor Perspectives in Medicine, 2, a006247, 26 p.
|
[11]
|
Wang, Y. and Mandelkow, E. (2016) Tau in Physiology and Pathology. Nature Reviews, 17, 5-21.
|
[12]
|
Aguzzi, A. and Callela, A.M. (2009) Prions: Protein Aggregation and Infectious Disease. Physiological Reviews, 89, 1105-1152.
https://doi.org/10.1152/physrev.00006.2009
|
[13]
|
Carrell, R.W. and Lomas, D.A. (2002) α1-Antitrypsin-Deficiency. New England Journal of Medicine, 346, 45-53. https://doi.org/10.1056/NEJMra010772
|
[14]
|
Jucker, M. and Walker, L.C. (2013) Self-Propagation of Pathogenic Protein Aggregation in Neurodegenerative Diseases. Nature, 501, 45-51.
https://doi.org/10.1038/nature12481
|
[15]
|
Pertinhez, T.A., Bouchard, M., Tomlinson, E.J., Wain, R., Ferguson, S.J., Dobson, C.M. and Smith, L.J. (2001) Amyloid Fibril Formation by a Helical Cytochrome. FEBS Letters, 495, 184-186. https://doi.org/10.1016/S0014-5793(01)02384-5
|
[16]
|
Sablon-Carrazana, M., Fernandez, I., Bencomo, A., Lara-Martinez, R., Rivera-Marrero, S., Dominguez, G., Perez-Perera, R., Jimenez-Garcia, L.F., Altamirano-Bustamante, N.F., Diaz-Delgado, M., Vedrenne, F., Rivillas-Acevedo, L., Pasten-Hidalgo, K., de Lourde Segura-Valdez, M., Islas-andradre, S., Garrido-Magana, E., Perera-Pintado, A., Prats-Capote, A., Rodriguez-Tanty, C. and Altamirano-Bustamante, M.M. (2015) Drug Development in Conformational Diseases: A Novel Family of Chemical Chaperons that Bind and Stabilize Several Polymorphic Amyloid Structures. PLOS One, 10, e0135292. https://doi.org/10.1371/journal.pone.0135292
|
[17]
|
Dani, M., Brooks, D.J. and Edison, P. (2016) Tau Imaging in Neurodegenerative Diseases. European Journal of Nuclear Medicine and Molecular Imaging, 43, 1139-1150. http://dx.doi.org/10.1007/s00259-015-3231-2
|
[18]
|
Oukoloff, K, Cieslikiewicz-Bouet, M., Chao, S., Da Costa Branquinho, E., Bouteiller, C., Ludovic, J. and Renard, P.-Y. (2015) PET and SPECT Radiotracers for Alzheimer’s Disease. Current Medicinal Chemistry, 22, 3278-3304.
https://doi.org/10.2174/0929867322666150805094645
|
[19]
|
Ishii, K. (2014) PET Approaches for Diagnosis of Dementia. American Journal of Neuroradiology, 9 p. (Online)
|
[20]
|
Bagchi, D.P., Yu, L., Permutter, J.S., Xu, J., Mach, R.H., Tu, Z. and Kotzbauer, P.T. (2013) Binding of the Radioligand SIL23 to Alpha Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasiblity and Screening Approaches for Developing a Parkinson Disease Imaging Agent. PLOS One, 8, e55031.
https://doi.org/10.1371/journal.pone.0055031
|
[21]
|
Ghaemmaghami, S., May, B.C.H., Renslo, A.R. and Prusiner, S.B. (2010) Discovery of 2 Aminothiazoles as Potent Anti-Prion Compounds. Journal of Virology, 84, 3408-3412. https://doi.org/10.1128/JVI.02145-09
|
[22]
|
Goldschmidt, L., Teng, P.K., Riek, R. and Eisenberg, D. (2010) Identifying the Amylome, Proteins Capable Forming Amyloid-Like Fibrils. PNAS, 107, 3487-3492.
https://doi.org/10.1073/pnas.0915166107
|
[23]
|
Gidalevitz, T., Kikis, E.A. and Morimoto, R.I. (2010) A Cellular Perspective on Conformational Disease: the Role of Genetic Background and Proteostasis Networks. Current Opinion in Structural Biology, 20, 23-32.
https://doi.org/10.1016/j.sbi.2009.11.001
|
[24]
|
Balbirnie, M., Grothe, R. and Eisenberg, D. (2001) An Amyloid-Forming Peptide from the Yeast Prion Sup 35 Reveals a Dehydrated β.Sheet Structure for Amyloid. Proceedings of the National Academy of Sciences, 98, 2375-2380.
https://doi.org/10.1073/pnas.041617698
|
[25]
|
Sawaya, M.R., Sambashivan, S., Nelson, R., Ivanova, M.L., Sievers, S.A., Balbiernie, M., Wiltius, J.J.W., McFarlane, H.T., Madsen, A.O., Riekel, C. and Eisenberg, D. (2007) Atomic Structure of Amyloid Cross-β-Spine Reveal Varied Steric Zippers. Nature, 447, 447-457. https://doi.org/10.1038/nature05695
|
[26]
|
Jarrett, J.T. and Lansbury Jr., P.T. (1993) Seeding “One Dimensional Crystallization” of Amyloid a Pathogenic Mechanism of Alzheimer’s Disease and Scrapie? Cell, 73, 1055-1058. https://doi.org/10.1016/0092-8674(93)90635-4
|
[27]
|
Baker, H.F., Ridley, R.M., Duchen, L.W., Crow, T.J. and Bruton, C.J. (1993) Evidence for the Transmission of Cerebral ß-Amyloidosis to Primates. International Journal of Experimental Pathology, 74, 441-454.
|
[28]
|
Aguzzi, A., Barres, B.A. and Bennett, M.L. (2013) Microglia: Scapegoat, Saboteur, or Something Else. Science, 339, 156-161. https://doi.org/10.1126/science.1227901
|
[29]
|
Nelson, R., Sawaya, M., Balbiernie, M., Madsen, A., Riekel, C., Grothe, R. and Eisenberg, D. (2005) Structure of the Cross-Beta Spine of Amyloid-Like Fibrils. Nature, 435, 773-778. https://doi.org/10.1038/nature03680
|
[30]
|
Rosetti, G., Bongarzone, S. and Carloni, P. (2013) Computational Studies on the Prion Proteins. Current Topics in Medicinal Chemistry, 13, 1-13.
https://doi.org/10.2174/15680266113136660170
|
[31]
|
Salloway, S., Mintzer, J., Weiner, M.F. and Cummings, J.L. (2008) Disease-Modifying Therapies in Alzheimer’s Disease. Alzheimer’s and Dementia, 4, 65-79.
https://doi.org/10.1016/j.jalz.2007.10.001
|
[32]
|
Saba Sheikh, S., Haque, E. and Mir, S.S. (2013) Neurodegenerative Diseases: Multifactorial Conformational Diseases and Their Therapeutic Interventions. Journal of Neurodegenerative Diseases, 2013, Article ID: 563481, 8 p.
|
[33]
|
Haass, C. and Selkoe, D.J. (2007) Soluble Protein Oligomers in Neurodegeneration: Lessons from the Alzheimer’s Amyloid ß-Peptide. Nature Reviews/Molecular Cell Biology, 8, 101-112. https://doi.org/10.1038/nrm2101
|
[34]
|
Mallucci, G., Dickinson, A., Linehan, J., Klohn, P.C., Brandner, S. and Collinge, J. (2003) Depleting Neuronal PrP Prion Infection Prevents Disease and Reverses Spongiosis. Science, 302, 871-874. https://doi.org/10.1126/science.1090187
|
[35]
|
Mallucci, G.R. (2009) Prion Neurodegeneration: Starts and Stops at the Synapse. Prion, 3, 195-201. https://doi.org/10.4161/pri.3.4.9981
|
[36]
|
Jucker, M. (2010) The Benefits and Limitations of Animal Models for Translational Research in Neurodegenerative Diseases. Nature Medicine, 16, 1210-1214.
https://doi.org/10.1038/nm.2224
|
[37]
|
Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., DeKosky, S.T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N.C., Galasko, D., Gauthier, S., Hampel, H., Jicha, G.A., Meguro, K., O’Brien, J., Pasquier, F., Robert, P., Salloway, S., Sarazin, M., de Souza, L.C., Stern, Y., Visser, P.J. and Scheltens, P. (2011) Revising the Definition of Alzheimer’s Disease: a New Lexicon. Lancet Neurology, 9, 1118-1127.
https://doi.org/10.1016/S1474-4422(10)70223-4
|
[38]
|
Braak, H. and Braak, E. (1995) Staging of Alzheimer’s Disease-Related Neurofibrillary Changes. Neurobiology of Aging, 16, 271-284.
https://doi.org/10.1016/0197-4580(95)00021-6
|
[39]
|
Braak, H., Braak, E., Bohl, J. and Reintjes, R. (1996) Age, Neurofibrillary Changes and ß Amyloid and the Onset of Alzheimers Disease. Neuroscience Letters, 210, 87-90. https://doi.org/10.1016/0304-3940(96)12668-9
|
[40]
|
McQuaid, S., Allen, I.V., McMahon, J. and Kirk. J. (1994) Association of Measles Virus with Neurofibrillary Tangles in Subacute Sclerosing Panencephalitis: a Combined in situ Hybridization and Immunocytochemical Investigation. Neuropathology and Applied Neurobiology, 20, 103-110.
https://doi.org/10.1111/j.1365-2990.1994.tb01168.x
|
[41]
|
Miklossy, J. (2015) Historic Evidence to Support a Causal Relationship between Spirochetal Infections and Alzheimer’s Disease. Frontiers in Aging Neuroscience. 7, Article 46, 12.
|
[42]
|
Ball, M.J., Lukiw, W.J., Kammerman, E.M. and Hill, J.M. (2013) Intracerebral Propagation of Alzheimer’s Disease: Strengthening Evidence of a Herpes Simplex Virus Etiology. Alzheimer’s Dementia, 9, 169-175.
https://doi.org/10.1016/j.jalz.2012.07.005
|
[43]
|
Itzhaki, R.F., Lathe, R., Balin, B.J., Ball, M.J., Bearer, E.L., Braak, H., Bullido, M.J., Clerici, M., Cosby, S.L., Del Tredici, K., Field, H., Fulop, T., Grassi, C., Griffin, W.S.T., Haas, J., Hudson, A.P., Kamer, A.R., Kell, D.B., Licastro, F., Letenneur, L., Lovheim, H., Mancuso, R., Miklossy, J., Otth, C., Palamara, A.T., Perry, G., Preston, C., Pretorius, E., Strandberg, T., Tabet, N., Taylor-Robinson, S.D. and Whittum-Hiudson, J.A. (2016) Microbes and Alzheimer’s Disease. Journal of Alzheimer’s Disease, 51, 979-984. https://doi.org/10.3233/JAD-160152
|
[44]
|
Dawkins, E. and Small, D.H. (2014) Insights into the Physiological Function of ß-Amyloid Precursors: Beyond Alzheimer’s Disease. Journal of Neurochemistry, 129, 756-769. https://doi.org/10.1111/jnc.12675
|
[45]
|
Pearson, H.A. and Peers, C. (2006) Physiological Roles for Amyloid ß Peptides. The Journal of Physiology, 5751, 5-10. https://doi.org/10.1113/jphysiol.2006.111203
|
[46]
|
Maji, S.K., Perrin, M.H., Sawaya, M.R., Jessberger, S., Vadodaria, K., Rissman, R.A., Singru, P.S., Nilsson, K.P., Simon, R., Schubert, D., Eisenberg, D., Rivier, J., Sawchenko, P., Vale, W. and Riek, R. (2009) Functional Amyloids as Natural Storage of Peptide Hormones Pituitary Secretory Granula. Science, 325, 328-332.
https://doi.org/10.1126/science.1173155
|
[47]
|
Fowler, D.M., Koulov, A.V., Balch, B.E. and Kelly, J.W. (2007) Functional Amyloid —From Bacteria to Humans. TIBS, 32, 217-223.
https://doi.org/10.1016/j.tibs.2007.03.003
|
[48]
|
Taylor, J.D. and Matthews, S.J. (2015) New Insight into the Molecular Control of Bacterial Functional Amyloids. Frontiers in Cellular and Infection Microbiology, 5, Article 33, 7 p.
|
[49]
|
Jaworski, T., Dewachter, I., Seymour, C.M., Borghgraef, P., Devijver, H., Kügler, S. and van Leuven, F. (2010) Alzheimer’s Disease: Old Problem, New Views from Transgenic to Viral Models. Biochimica Biophysica Acta, 1802, 808-818.
https://doi.org/10.1016/j.bbadis.2010.03.005
|
[50]
|
Trudler, D., Farfara, D. and Frenkel, D. (2010) Toll-Like Receptors Expression and Signaling in Glia Cells in Neuro-Amygdalogenic Diseases: Toward Future Therapeutic Applications. Mediators of Inflammation, Article ID: 497987, 12 p.
|
[51]
|
Heneka, M.T., Carson M.J., El Khoury J., Landreth, G.E., Brosseron , F., Feinstein, D.L., Jacobs, A.H., Wyss-Coray, T., Vitorica J., Ransohoff, R.M., Herrup, K., Frautschy, S., Finsen, B., Brown , G.C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G.C., Town, T., Morgan , D., Shinohara, M.L., Perry, V.H., Holmes, C., Bazan, N.G., Brooks , D.J., Hunot, S., Joseph, B., Deigendesch, N., Karaschuk, O., Boddeke, E., Dinarello, C.A., Breitner, J.C., Cole, G.M., Golenbock, D.T. and Kummer, M.P. (2015) Neuroinflammation in Alzheimer’s Disease. The Lancet Neurology, 14, 388-405. https://doi.org/10.1016/S1474-4422(15)70016-5
|
[52]
|
Swerdlow, R.H., Burns, J.M. and Khan, S.M. (2014) The Alzheimer’s Disease Mitochondrial Cascade Hypothesis: Progress and Perspectives. Biochimica Biophysica Acta, 1842, 1219-1231. https://doi.org/10.1016/j.bbadis.2013.09.010
|
[53]
|
Swerdlow, R.H. and Khan, S.M. (2004) A Mitochondrial Cascade Hypothesis for Sporadic Alzheimer’s Disease. Medical Hypotheses, 63, 8-20.
https://doi.org/10.1016/j.mehy.2003.12.045
|
[54]
|
Howlett, G.J. and Moore, K.J. (2006) Untangling the Role of Amyloid in Atherosclerosis. Current Opinions in Lipidology, 17, 541-547.
https://doi.org/10.1097/01.mol.0000245260.63505.4f
|
[55]
|
De la Torre, J.C. (2013) Vascular Risk Factors: A Ticking Time Bomb to Alzheimer’s Disease. American Journal of Alzheimer’s Disease Other Dementia, 28, 551-559. https://doi.org/10.1177/1533317513494457
|
[56]
|
Iqbal, K., Liu, F. and Gong, C.-X. (2016) Tau and Neurodegenerative Disease: The Story so Far. Nature Reviews, 12, 15-27.
|
[57]
|
Fodero-Tavoletti, M.T., Brockschnieder, D., Villemagne, V.L., Martin, L., Connor, A.R., Thiele, A., Berndt, M., McLean, C.A., Krause, S., Rowe, C.C., Masters, C.L., Dinkelborg, L., Dyrks, T. and Cappai, R. (2012) In Vitro Characterization of [18F]-florbetaben, an Abeta Imaging Radiotracer. Nuclear Medicine and Biology, 39, 1042-1048. https://doi.org/10.1016/j.nucmedbio.2012.03.001
|
[58]
|
Melki, R. (2015) Role of Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases. Journal of Parkinson's Disease, 5, 217-227.
https://doi.org/10.3233/JPD-150543
|
[59]
|
Bucciantini, M., Nosi, D., Forzan, M., Russo, E., Calamai, M., Pieri. L, Formigli, L., Quercioli, F., Soria, S., Pavone, F., Savistchenko, J., Melki, R. and Stefani, M. (2012) Toxic Effects of Amyloid Fibrils on Cell Membranes. FASEB Journal, 26,818-831.
https://doi.org/10.1096/fj.11-189381
|
[60]
|
Berthelot, K., Cullin, C. and Lecomte, S. (2013) What Does Make an Amyloid Toxic: Morphology, Structure or Interaction with Membrane? Biochimie, 95, 12-19.
https://doi.org/10.1016/j.biochi.2012.07.011
|
[61]
|
Cecchi, C. and Stefani, M. (2013) The Amyloid Cell-Membrane System. The Interplay between the Biophysical Features of Oligomeric/Fibrils and Cell Membrane Defines Amyloid Toxicity. Biophysical Chemistry, 182, 30-43.
https://doi.org/10.1016/j.bpc.2013.06.003
|
[62]
|
Jiang, H., Wang, X., Hunang, L., Su, T. and Li, X. (2011) Benzenediol Berberine Hybrides: Multifunctional Agents for Alzheimer’s Disease. Bioorganic & Medicinal Chemistry, 19, 7228-72235. https://doi.org/10.1016/j.bmc.2011.09.040
|
[63]
|
Durairajan, S.S.K., Liu, L.-F., Lu, J.-H., Chen, L.-L., Yuan, Q., Chung, S.K., Huang, L., Li, X.-S., Huang, J.-D. and Li, M. (2012) Berberine Ameliorates ß-Amyloid Pathology, Gliosis and Cognitive Impairment in an Alzheimer’s Disease Transgenic Mouse Model. Neurobiology of Aging, 33, 2903-2919.
https://doi.org/10.1016/j.neurobiolaging.2012.02.016
|
[64]
|
Yiannopoulou, K.G. and Papageorgiou, S. (2013) Current and Future Treatments for Alzheimer’s Disease. Therapeutic Advances in Neurological Disorders, 6, 19-33.
https://doi.org/10.1177/1756285612461679
|
[65]
|
Bolognesi, M.L., Gandini, A., Prati, F. and Uliassi, E. (2016) From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer’s Disease? Journal of Medicinal Chemistry, 59, 7759-7770. https://doi.org/10.1021/acs.jmedchem.6b00151
|
[66]
|
Aulic, S., Bolognesi, M.L. and Legname, G. (2013) Small Molecule Theranostic Probes: A Promising Future in Neurodegenerative Diseases. International Journal of Cell Biology, 2013, Article ID: 150952. https://doi.org/10.1155/2013/150952
|
[67]
|
Staderini, M. (2015) New Molecular Scaffolds for Antineurodegenerative Drug Discovery. PhD Thesis, Universidad Complutense de Madrid, Madrid.
|
[68]
|
Jovalekic, A., Koglin, N., Mueller, A. and Stephens, A.W. (2016) New Protein Deposition Tracers in the Pipeline. EJNMMI Radiopharmacy and Chemistry, 1, 12 p.
|
[69]
|
Arora, A. and Bhagat, N. (2016) Insight into the Molecular Imaging of Alzheimer’s Disease. International Journal of Biomedical Imaging, 2016, Article ID: 7462014, 17 p.
|
[70]
|
Villemagne, V.L. and Okamura, N. (2014) In Vivo Tau Imaging: Obstacles and Progress. Alzheimer’s & Dementia, 10, S254-S264.
https://doi.org/10.1016/j.jalz.2014.04.013
|
[71]
|
Truong, P.M., Viet, M.H., Nguyen, P.H., Hu, C.-K. and Li, S.M. (2014) Effect of Taiwan Mutation (D7H) on Structures of Amyloid-ß Peptides: Replica Exchange Molecular Dynamics Study. Journal of Physical Chemistry, 118, 8972-8981.
https://doi.org/10.1021/jp503652s
|
[72]
|
Epis, R., Gardoni, F., Gardoni, F., Marcello, E., Genazzani, A., Canonico, P.L. and Di Luca, M. (2010) Searching for New Animal Models of Alzheimer’s Disease. European Journal of Pharmacology, 626, 57-63.
https://doi.org/10.1016/j.ejphar.2009.10.020
|
[73]
|
Galimberti, D. and Scarpini, E. (2010) Treatment of Alzheimer’s Disease: Symptomatic and Disease-Modifying Approaches. Current Aging Science, 3, 46-56.
https://doi.org/10.2174/1874609811003010046
|
[74]
|
Liu, H.-L., Wu, C.-C., Zhao, J.-H., Liu, Y.-F., Huang, C.-H., Fang, H.-W. and Ho, Y. (2007) Insights into Conformational Changes of Several Human Lysozyme Variants Associated with Hereditary Associated Amyloidosis. Biotechnology Progress, 23, 246-254. https://doi.org/10.1021/bp060264a
|
[75]
|
Ossenkoppele, R., Schonhaut, D.R., Scholl, M., Lockhart, S.N., Ayakta, N., Baker, S.L., O’Neil, J.P., Janabi, M., Lazaris, A., Cantwell, A., Vogel, J., Santos, M., Miller, Z.A., Bettcher, B.M., Vossel, K.A., Kramer. J.H., Gorno-Tempini, M.L., Miller, B.L., Jagust, W.J. and Rabinovici, G.D. (2016) Tau PET Patterns Mirror Clinical and Neuroanatomical Variability in Alzheimer’s Disease. Brain, 139, 1551-1567.
https://doi.org/10.1093/brain/aww027
|
[76]
|
Small, G.W., Kepe, V., Ercolim, L.M., Siddarth, P., Bookheimer, S.Y., Miller, K.J., Lavretsky, H., Burggren, A.C.,Cole, G.M., Vinters, H.V., Thompson, P.M., Huang, S.C., Satyamurthy, N., Phelps, M.E. and Barrio, J.R. (2006) PET of Brain Amyloid and Tau in Mild Cognitive Impairment. New England Journal of Medicine, 355, 2652-2663. https://doi.org/10.1056/NEJMoa054625
|
[77]
|
Jahn, T.R., Tennent, J.A. and Radford, S.E.A. (2008) Common ß Sheet Architecture Underlies In Vitro and In Vivo ß2-Microglobulin Amyloid Fibrils. Journal of Biological Chemistry, 283, 17279-17286. https://doi.org/10.1074/jbc.M710351200
|
[78]
|
Bennhold, H. (1922) Specific Staining of Amyloid by Congo Red. Münchener Medizinische Wochenschrift, 69, 1537-1538.
|
[79]
|
Divry, P. (1927) Etude Histochemique de Plaques Seniles. Journal Belge De Neurologie Et De Psychiatrie, 27, 643-657.
|
[80]
|
Khurana, R., Uversky, V.N., Nielsen, L. and Fink, A.L. (2001) Is Congo Red an Amyloid-Specific Dye? Journal Biological Chemistry, 276, 22715-22721.
https://doi.org/10.1074/jbc.M011499200
|
[81]
|
Puchtler, H., Sweat, F. and Levine, M.J. (1962) On the Binding of Congo Red by Amyloid. Journal of Histochemistry & Cytochemistry, 10, 355-363.
https://doi.org/10.1177/10.3.355
|
[82]
|
Brier, M.R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Yi, S., Hassenstab, J., Cairns, N.J., Holtzman, D.M., Fagan, A.M., Morris, J.C., Benzinger, T.L.S. and Ances, B.M. (2016)Tau and Aß Imaging , CSF Measures , and Cognition in Alzheimer’s Disease. Science Translational Medicine, 6, 338ra66.
|
[83]
|
Edwards, R.A. and Woody, R.W. (1977) Induced Circular Dichroism as a Probe of Cibacron Blue and Congo Red Bound to Dehydrogenases. Biochemical and Biophysical Research Communications, 79, 470-476.
https://doi.org/10.1016/0006-291X(77)90181-4
|
[84]
|
Bancroft, J.D. and Gamble, M. (2008) Theory and Practice of histological Techniques. Elsevier, Churchill Livingston.
|
[85]
|
Wu, C., Scott, J. and Shea, J.-E. (2012) Binding of Congo Red to Amyloid Protofibrils of the Alzheimer Aß 9-40 Peptide Probed by Molecular Dynamic Simulations. Biophysical Journal, 103, 550-557. https://doi.org/10.1016/j.bpj.2012.07.008
|
[86]
|
Lendel, C., Bolognesi, B., Wahlstrom, A., Dobson, C.M. and Groslund, A. (2010) Detergent-Like Interaction of Congo Red with the Amyloid ß Peptide. Biochemistry, 49, 1358-1360. https://doi.org/10.1021/bi902005t
|
[87]
|
Reinke, A.A. and Gestwicki, J.E.. (2011) Insight into Amyloid Structure Using Chemical Probes. Chemical Biology & Drug Design, 77, 399-411.
https://doi.org/10.1111/j.1747-0285.2011.01110.x
|
[88]
|
Klunk, W.E., Lopresti, B.J., Ikonomovic, M.D., Levterov, I.M., Koldamova, R.P., Abrahamson, E.E., Debnath, M.I., Holt, D.B., Huang, G.-F., Shao, L., DeKosky, S.T., Price, J.C. and Matthis, C.A. (2005) Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid β in Alzheimer’s Disease Brain but not in Transgenic Mouse Brain. Journal of Neuroscience, 25, 10598-10606. https://doi.org/10.1523/JNEUROSCI.2990-05.2005
|
[89]
|
Rokka, J., Snellman, A., Zona, C., La Ferla, B., Nicotra, F., Salmona, M., Forloni, G., Haaparanta-Solin, M., Rinne, J.O. and Solin, O. (2014) Synthesis and Evaluation of a 18F-Curcumin Derivative for Amyloid Plaque Imaging. Bioorganic & Medicinal Chemistry, 22, 2753-2762. https://doi.org/10.1016/j.bmc.2014.03.010
|
[90]
|
Harrison, S.T., Mulhearn, J., Wolkenberg, S.E., Miller, P.J., O’Malley, S.S., Zeng ,Z., Williams, D.L., Hostetler, E.D., Sanabria-Bohorquez, S., Gammage, L., Fan, H., Sur, C., Culberson, J.C., Hargreaves, R.J., Cook, J.J., Hartman, G.D. and Barrow, J.C. (2011) Synthesis and Evaluation of 5-Fluoro-2 Aryloxazolo[5,4-b]Pyridines as ß Amyloid PET Ligands and Identification of MK-3328. ACS Medicinal Chemistry Letters, 2, 498-502. https://doi.org/10.1021/ml200018n
|
[91]
|
Ni, R., Gillberg, P.-G., Bergfors, A., Marutle, A. and Nordberg, A. (2013) Amyloid Tracers Detect Multiple Binding Sites in Alzheimer’s Disease Brain Tissue. Brain, 136, 2217-2227. https://doi.org/10.1093/brain/awt142
|
[92]
|
Hostetler, E.D., Sanabria-Bohorquez, S., Fan, H., Zebg, Z., Gammage, L., Miller, P., O’Malley, S., Connolly, B., Mulhearn, J., Harrison, S.T., Wolkenberg, S.E., Barrow, J.C., Williams, D.L., Hargreaves, R.J., Sur, C. and Cook, J.J. (2011) [18F]Fluoroazabezoxazoles as Potential Amyloid Plaque PET Tracers: Synthesis and in Vivo Evaluation in Rhesus Monkeys. Nuclear Medicine and Biology, 38, 1193-1203.
https://doi.org/10.1016/j.nucmedbio.2011.04.004
|
[93]
|
Pissarek, M. and Disko, U. (2013) Non-Peptide Ligands in the Characterization of Peptide Receptors at the Interface between Neuroendocrine and Mental Diseases. WJNS, 3, 100-125. https://doi.org/10.4236/wjns.2013.32014
|
[94]
|
Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (1997) Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug discovery and Development Settings. Advanced Drug Delivery Reviews, 23, 3-25.
https://doi.org/10.1016/S0169-409X(96)00423-1
|
[95]
|
Harada, R., Okamura, N., Furumoto, S., Tago, T., Maruyama, M., Higuchi, M., Yoshikawa, T., Arai, H., Iwata, R., Kudo, Y. and Yanai, K. (2013) Comparison of the Binding Characteristics of [18F]THK-523 and other Amyloid Imaging Tracers to Alzheimer’s Disease Pathology. European Journal of Nuclear Medicine and Molecular Imaging, 40, 125-132. https://doi.org/10.1007/s00259-012-2261-2
|
[96]
|
Shoghi-Jadid, K., Small, G.W., Agdeppa, E.D., Kepe, V., Ercoli, L.M., Siddarth, P., Read, S., Sathyamurthy, N., Petric, A., Huang, S.-C. and Barrio, J.R. (2002) Localization of Neurofibrillary Tangles and beta-Amyloid Plaques in the Brains of Living Patients with Alzheimer Disease. American Journal of Geriatric Psychiatry, 10, 24-35. https://doi.org/10.1097/00019442-200201000-00004
|
[97]
|
Henriksen, G., Hauser, A.I., Westwell, A.D., Yousefi, B.H., Schwaiger, M., Drzega, A. and Wester, H.-J. (2007) Metabolic Stabilized Benzothiazoles for Imaging of Amyloid Plaques. Journal of Medicinal Chemistry, 50, 1087-1089.
https://doi.org/10.1021/jm061466g
|
[98]
|
Neumaier, B., Deisenhofer, S., Sommer, C., Solbach, C., Reske, S.N. and Mottaghy, F. (2010) Synthesis and Evaluation of 18F-Fluoroethylated Benzothiazole Derivatives for Imaging of Amyloid Plaques in Alzheimer’s Disease. Applied Radiation and Isotopes, 68, 1066-1072. https://doi.org/10.1016/j.apradiso.2009.12.044
|
[99]
|
Barrio, J.R., Small, G.W., Wong, K.-P., Huang, S.-C., Liu, J., Merrill, D.A., Giza, C.C., Fitzsimmons, R.P., Omalu, B., Bailes, J. and Kepe, V. (2015) In Vivo Characterization of Chronic Traumatic Encephalopathy Using [18F]FDDNP PET Brain Imaging. PNAS, 112, E2039-E2047. https://doi.org/10.1073/pnas.1409952112
|
[100]
|
Agdeppa, E.D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N. and Petric, A. (2001) Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphtylethy-liden Derivatives as Positron Emission Tomography Imaging Probes for Beta Amyloid Plaques in Alzheimer’s Disease. Journal of Neuroscience, 21, RC 189: 1-5.
|
[101]
|
Maruyuma, M., Shimada, H., Suhara, T., Shinoto, H., Maeda, J., Zhang, M.-R., Trojanowski, J.Q., Lee, V.M.-Y., Masomoto, K., Takano, H., Sahara, N., Iwata, N., Okamura, N., Furumoto, S., Kudo, Y., Chang, Q., Saido, T.C., Takashima, A., Lewis, J., Jang, M.-K., Aoki, I., Ito, H. and Higuchi, M. (2013) Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. Neuron, 79, 1094-1108. https://doi.org/10.1016/j.neuron.2013.07.037
|
[102]
|
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstrom, M., Savitchera, I., Huang, G.-F., Estrada, S., Ausen, B., Debnath, M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A. and Langstrom, B.(2004) Imaging Brain Amyloid in Alzheimer’s Disease with Pittsburgh Compound-B. Annals of Neurology, 55, 306-319.
https://doi.org/10.1002/ana.20009
|
[103]
|
Klunk, W.E., Wang, J., Huang, G.-F., Debnath, M.L., Holt, D.P., Shao, L., Hamilton, R.L., Ikonomovic, M.D., DeKosky, S.T. and Mathis, C.A. (2003) The Binding of 2-(4-Methylaminopheny)Benzothiazole to Postmortem Brain Homogenates is Dominated by the Amyloid Component. Journal of Neuroscience, 23, 2086-2092.
|
[104]
|
Kudo, Y., Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K., Maruyuma, M., Itoh, M., Iwata, R., Yanai, K. and Arai, H. (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6-(2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for in Vivo Detection of Defense Amyloid Plaques in Alzheimer’s Disease Patients. Journal of Nuclear Medicine, 48, 553-561. https://doi.org/10.2967/jnumed.106.037556
|
[105]
|
Kepe, V., Moghbel, M.C., Langstrom, B., Zaidi, H., Vinters, H.V., Huang, S.-C., Satyamurthy, N., Doudet, D., Mishani, E., Cohen, R.M., Holund-Carlsen, P.F., Alavi, A. and Barrio, J.R., (2013) Amyloid-ß Positron Emission Tomography Imaging Probes: A Critical Review. Journal of Alzheimer’s Disease, 36, 613-663.
|
[106]
|
Wong, D.F., Mogekhar, A.R., Rigamonti, D., Brasic, J.R., Rousset, O., Willis, W., Buckley, C., Smith, A., Gok, B., Sherwin, P. and Grachev, I.D. (2013 ) An in vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients. Molecular Imaging and Biology, 15, 230-237.
https://doi.org/10.1007/s11307-012-0583-x
|
[107]
|
Berndt, U., Stanetty, C., Wanek, T., Kuttner, C., Stanek, J., Berger, M., Bauer, M., Henriksen, G., Wester, H.-J., Karterni, K.H., Angelberger, P. and Noe, C. (2008) Synthesis of a [18F]Fluorobenzothiazole as Potential Amyloid Imaging Agent. Journal of Labelled Compounds and Radiopharmaceuticals, 51, 137-145.
https://doi.org/10.1002/jlcr.1476
|
[108]
|
Zheng, M.-Q., Yin, D.-Z., Qiao, J.-P., Zhang, L. and Wang, Y.-X. (2008a) Syntheses and Evaluation of Fluorinated Benzothiazoleanilines as Potential Tracers for ß-Amyloid Plaques in Alzheimer’s Disease. Journal of Fluorine Chemistry, 129, 210-216. https://doi.org/10.1016/j.jfluchem.2007.11.005
|
[109]
|
Zheng, M.Q., Yin, D.Z., Zhang, L., Lei, B, Cheng, D.-F., Cai, H.-C., Han, Y.-J., Wu, M.-X., Zhang, H. and Wang, J. (2008b) Biologicalcharacters of [18F]O-FEt-PIB in a Rat Model of Alzheimer’s Disease Using Micro-PET-Imaging. Acta Pharmacologica Sinica, 29, 548-554. https://doi.org/10.1111/j.1745-7254.2008.00785.x
|
[110]
|
Nyberg, S., Jornhagen, M.E., Cselenyi, Z., Halldin, C., Julin, P., Olsson, H., Freund-Levi, Y., Andersson, J., Varnas, K., Svensson, S. and Farde, L. (2009) Detection of Amyloid in Alzheimer’s Disease with Positron Emission Tomogragphy Using [11C]AZD2184. European Journal of Nuclear Medicine and Molecular Imaging, 36, 1859-1863. https://doi.org/10.1007/s00259-009-1182-1
|
[111]
|
Verhoeff, N.P., Wilson, A.A., Takeshita, S., Trop, L., Hussey, D., Singh, K., Kung, H.F., Kung, M.P. and Houle, S. (2004) In Vivo Imaging of Alzheimer Disease Beta-Amyloid with [11C]SB-13 PET. American Journal of Geriatric Psychiatry, 12, 584-595.
|
[112]
|
James, O.G., Doraiswamy, P.M. and Borges-Neto, S. (2015) PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies. Frontiers in Neurology, 6, Article 38.
|
[113]
|
Yang, L., Rieves, D. and Ganley, C. (2012) Brain Amyloid Imaging-FDA Approval of Flobetapir F18 Injection. New England Journal of Medicine, 367, 885-887.
https://doi.org/10.1056/NEJMp1208061
|
[114]
|
Sander, K., Lashley, T., Gami, P., Gendron, T., Lythgoe, M.F., Rohrer, J.D., Schott, J.M., Revesz, T., Fox, N.C. and Arstad, E. (2016) Characterization of Tau Positron Emission Tomography Tracer [18F]AV-1451 Binding to Postmortem Tissue in Alzheimer’s Disease, Primary Tauopathies, and Other Dementias. Alzheimer’s & Dementia, 12, 116-1124. https://doi.org/10.1016/j.jalz.2016.01.003
|
[115]
|
Reiman, E.M., Quiroz, Y.T., Fleisher, A.S., Chen, K., Velez-Pardo, C., Jimenez-Del-Ri, M., Fagan, A.M., Shah, A.R., Alvarez, S., Arbelaez, A., Girald, M., Acoster-Baena, N., Sperling, R.A., Dickerson, B., Stern, C.E., Tirado, V., Munoz, C., Reiman, R.A. and Huentelman, M. (2012) Brain Imaging and Fluid Biomarker Analysis in Young Adults at Genetic Risk for Autosomal Dominant Alzheimer’s Disease in the Presenilin 1 E280A Kindred: a Case-Control Study. The Lancet Neurology, 11, 1048-1056. https://doi.org/10.1016/S1474-4422(12)70228-4
|
[116]
|
Fleisher ,A.S., Chen, K., Quiroz, J.T., Jakimovitch, L.J., Gomez, M.G., Langois, C.M., Langbaum, J.B.S., Ayutyanont, N., Roontiva, A., Tiyyagura, P., Lee, W., Mo, H, Lopez, L., Moreno, S., Acosta-Baena, N., Giraldo, M., Garcia, G., Reiman, R.A., Huentelman, M.J., Kosik, K.S., Tairot, P.N., Lopera, F. and Reiman, E.M. (2012) Florbetapir PET Analysis of Amyloid Aß Deposition in the Presenilin 1 E280a Autosomal Dominant Alzheimer’s Disease Kindred: a Cross Sectional Study. Lancet, 11, 1057-1065. https://doi.org/10.1016/S1474-4422(12)70227-2
|
[117]
|
Jureus, A., Swahn, B.-M., Sandell, J., Jeppson, F., Johnson, A.F., Johnstrom, P., Neelissen, J.A.M., Sunnemark, D., Farde, L. and Svensson, S. (2010) Characterization of AZD4694, a Novel Fluorinated Aß Plaque Neuroimaging PET Radioligand. Journal of Neurochemistry, 114, 784-794. https://doi.org/10.1111/j.1471-4159.2010.06812.x
|
[118]
|
Sabri, O., Seibyl, J., Rowe, C. and Barthel, H. (2015) Beta-Amyloid Imaging with Florbetaben. Clinical and Translational Imaging, 3, 13-26.
https://doi.org/10.1007/s40336-015-0102-6
|
[119]
|
Zhu, L., Ploessel, K. and Kung, H.F. (2014) PET/SPECT Imaging Agents for Neurodegerative Diseases. Chemical Society Reviews, 43, 6683-6691.
https://doi.org/10.1039/C3CS60430F
|
[120]
|
Furumoto, S., Okamura, N., Furukawa, K., Tashiro, M., Ishikawa, Y., Sugi, K., Tomita, N., Waragai, M., Harada, R., Tago, T., Iwata, R., Yanai, K., Arai, H. and Kudo, Y. (2013) A 18F-Labeled BF-227 Derivative as a Potential Radioligand for Imaging Dense Amyloid Plaques by Positron Emission Tomography. Molecular Imaging and Biology, 15, 497-506. https://doi.org/10.1007/s11307-012-0608-5
|
[121]
|
Yousefi, B.H., von Reutern, B., Scherübl, D., Manook, A., Schwaiger, M., Grimmer, T., Henriksen, G., Forster, S., Drzezga, A. and Wester, H.-J. (2015) FIBT versus Florabetaben and PIB: A Preclinical Comparison Study with Amyloid PET in Transgenic Mice. EJNMMI Research, 5, 13 p.
|
[122]
|
Ono, M., Cheng, Y., Kimura, H., Cui, M., Kagawa, S., Nishii, R. and Saji, H. (2011) Novel 18F-labeled Benzofuran Derivatives with Improved Properties for Positron Emission Tomography (PET) Imaging of ß-Amyloid Plaques in Alzheimer’s Brains. Journal of Medicinal Chemistry, 54, 2971-2979. https://doi.org/10.1021/jm200057u
|
[123]
|
Weingarten, M.D., Lockwood, A.H., Hwo, S.Y. and Kirschner, M.W. (1975) A Protein Factor Essential for Microtubule Assembly. Proceedings of the National Academy of Sciences USA, 72, 1858-1862. https://doi.org/10.1073/pnas.72.5.1858
|
[124]
|
Huang, Y., Wu, Z. and Zhou, B. (2016) Behind the Curtain of Tauopathy: A Show of Multiple Players Orchestrating Tau Toxicity. Cellular and Molecular Life Sciences, 73, 1-21. https://doi.org/10.1007/s00018-015-2042-8
|
[125]
|
Xia, C. and Dickerson, B.C. (2016) Tau PET: The Next Frontier in Imaging of Dementia. International Psychogeriatrics, 28, 1403-1406.
https://doi.org/10.1017/S1041610216000880
|
[126]
|
Johnson, K.A., Schultz, A., Betensky, R.A., Becker, J.A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., Marshall, G., Albers, M., Mauro, S., Pepin, L., Alverio, J., Judge, K., Philiossaint, M., Soup, T., Yokell, D., Dickerson, B., Gomez-Isla, T., Hyman, B., Vasdev, N. and Sperling, R. (2016) Tau Positron emission Tomographic Imaging in Aging and Early Alzheimer Disease. Annals of Neurology, 79, 110-119. https://doi.org/10.1002/ana.24546
|
[127]
|
Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt, D.P. and Mathis, C.A. (2001) Uncharged Thioflavin-T Derivatives Bind to Amyloid-Beta Protein with High Affinity and Readily Enter the Brain. Life Sciences, 69, 1471-1484.
https://doi.org/10.1016/S0024-3205(01)01232-2
|
[128]
|
Tago, T., Furumoto, S., Okamura, N., Harada, R., Adachi, H., Ishikawa, Y., Yanai, K., Iwata, R. and Kudo, Y. (2016) Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease. Journal of Nuclear Medicine, 57, 608-614. https://doi.org/10.2967/jnumed.115.166652
|
[129]
|
Duykaerts, C., Brion, C.P., Hauw, J.J. and Falment-Durand, J. (1987) Quantitative Assessment of the Density of Neurofibrillary Tangles and Senile Plaques in Dementia of the Alzheimer Type. Comparison of Immunocytochemistry with a Specific Antibody and Bodian’s Protargol Method. Acta Neuropathologica, 73, 167-170.
https://doi.org/10.1007/BF00693783
|
[130]
|
Hostetler, E.D., Walji, A.M., Zeng, Z., Miller, P., Bennacef, I., Salinas, C., Connolly, B., Gantert, L., Haley, H., Holahan, M., Purcell, M., Riffel, K., Lohith, T.G., Coleman, P., Soriano, A., Ogawa, A., Xu, S., Zhang, X., Joshi, E., Della Rocca, J., Hesk, D., Schenk, D.J. and Evelhoch, J.L. (2016) Preclinical Characterization of 18F-MK-6240, a Promising Positron Emission Tomography (PET) Tracer for in vivo Quantification of Human Neurofibrillary Tangles (NFTs). Journal of Nuclear Medicine, 57, 1599-1606. https://doi.org/10.2967/jnumed.115.171678
|
[131]
|
Luna-Munoz, J., Chavez-Mazias, L., Garcia-Sierra, F. and Mena, R. (2007) Earliest Stages of Tau Conformational Changes are Related to the Appearance of the Sequence of Specific Phosphor-Dependent Tau Epitopes in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 12, 365-375.
|
[132]
|
Kolb, H., Attardo, G., Mintun, M., Chien, D., Elizarov, A., Conti, P., Miller, C., Joshi, A. and Skovronsky, D. (2013) First Case Report: Imaging to Autopsy Correlation for Tau Imaging with T808 (A-680). Alzheimer’s & Dementia, 9, 844-845.
https://doi.org/10.1016/j.jalz.2013.08.008
|
[133]
|
Chien, D.T., Szardennings, A.K., Bahri, S., Walsh, J.C., Mu, F., Xia, C., Shankle, W.R., Lerner, A.J., Su, M.-Y., Elizarov, A. and Kolb, H.C. (2014) Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [18F]-T808. Journal of Alzheimer’s Disease, 38, 171-184.
|
[134]
|
Okamura, N., Furumoto, S., Fodero-Tavoletti, M.T., Mulligan, R.S., Harada, R., Yates, P., Pejoska, S., Kudo, Y., Masters, C.L., Yanai, K., Rowe, C.C. and Villemagne, V.L. (2014) Non-Invasive Assessment of Alzheimer’s Disease Neurofibrillary Pathology Using 18F-THK5105 PET. Brain, 137, 1762-1771.
https://doi.org/10.1093/brain/awu064
|
[135]
|
Walji, A.M., Hostetler, E.D. , Selnick, H., Zeng, Z. , Miller, P., Bennacef, I., Salinas, C., Connolly, B., Gantert, L., Holahan, M., O’Malley, S., Purcell, M., Riffel, K., Li, J., Balsells, J., O’Brien, J.A., Melquist, S., Soriano, A., Zhang, X., Ogawa, A., Xu, S., Joshi, E., Della Rocca, J., Hess, F.J., Schachter, J., Hesk, D., Schenk, D., Struyk, A., Babaoglu, K., Lohith, T.G., Wang, Y., Yang, K., Fu, J., Evelhoch, J.L. and Coleman, P.J. (2016) Discovery of 6-(Fluoro-18F-3-(1H-Pyrrolo[2,3-c]Pyridine-1-yl)Isoquinolin-5-Amine ([18F]-MK-6240): a Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs). Journal of Medicinal Chemistry, 59, 4778-4789. https://doi.org/10.1021/acs.jmedchem.6b00166
|
[136]
|
Wagner, T.T., Hou, X., Verhoest, P.R. and Villabos, A. (2010) Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach to Enable Alignment of Druglike Properties. ACS Chemical Neuroscience, 1, 435-449. https://doi.org/10.1021/cn100008c
|
[137]
|
Wagner, T.T., Hou, X., Verhoest, P.R. and Villabos, A. (2016) Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery. ACS Chemical Neuroscience, 7, 767-775.
https://doi.org/10.1021/acschemneuro.6b00029
|
[138]
|
Spillantini, M.G., Divane, A. and Goedert, M. (1995) Assignment of Human Alpha-Synuclein (SNCA) and Beta-Synuclein (SNCB) Genes to Chromosomes 4q21 and 5q35. Genomics, 27, 379-381. https://doi.org/10.1006/geno.1995.1063
|
[139]
|
Shah, M., Seibyl, J., Cartier, A., Bhatt, R. and Catafau, A.M. (2014) Molecular Imaging Insights into Neurodegeneration: Focus on Alpha Synuclein Radiotracers. Journal of Nuclear Medicine, 55, 1-4.
|
[140]
|
Jellinger, K.A. (2009) A Critical Review of Current Staging α-Synuclein Pathology in Lewy Body Disorders. BBA, 1792, 730-740.
|
[141]
|
Vernon, A.C., Ballard, C. and Modo, M. (2010) Neuroimaging for Lewy Body Disease: Is the In Vivo Molecular Imaging of Synuclein Neuropathology required and feasible? Brain Research Reviews, 65, 28-55.
https://doi.org/10.1016/j.brainresrev.2010.05.006
|
[142]
|
Hoehn, M. and Yahr, M. (1967) Parkinsonism: onset, progression and mortality.. Neurology, 17, 427-442. https://doi.org/10.1212/WNL.17.5.427
|
[143]
|
Eberling, J.L., Dave, K.D. and Frasier, M.A. (2013) α-Synuclein Imaging: A Critical Need for Parkinson’s Disease Research. Journal of Parkinson’s Disease, 3, 565-567.
|
[144]
|
Massano, J. and Bathia, K.P. (2012) Clinical Approach to Parkinson’s Disease: Features, Diagnosis and Principles of Management. Cold Spring Harbor Perspectives in Medicine, 2, a008870, 15 p.
|
[145]
|
Prusiner, S.B. (1997) Prion Disease and the BSE Crisis. Science, 278, 245-251.
https://doi.org/10.1126/science.278.5336.245
|
[146]
|
Kepe, V., Ghetti, B., Farlow, M.R., Bresjanac, M., Miller, K., Huang, S.-C., Wong, K.-P., Murrell, J.R., Piccardo, P., Epperson, F., Repovs, G., Smid, L.M., Petric, A., Siddarth, P., Liu, J., Sataymurthy, N., Small, G.W. and Barrio, J.R. (2010) PET of Brain Prion Protein Amyloid in Gerstmann-Straussler-Scheinker Disease. Brain Pathology, 20, 419-430. https://doi.org/10.1111/j.1750-3639.2009.00306.x
|
[147]
|
Wagner, J., Ryazanov, S, Leonov, A., Levin, J., Shi, S., Schmidt, F., Prix, C., Pan-Montojo, F., Bertsch, U., Mitteregger-Kretzschar, G., Geissen, M., Eiden, M., Leidel, F., Hirschberger, T., Deeg, A.A., Krauth, J., Zinth, W., Tavan, P., Pilger, J., Zweckstetter, M., Frank, T., Bohr, K., Weishaupt, J.H., Uhr, M., Urlaub, H., Teichmann, U., Samwer, M., Botzel, K., Groschup, M., Kretzschmar, H., Griesinger, C. and Giese, A. (2013) Anle138b: A Novel Oligomer Modulator for Disease-Modifying Therapy of Neurodegenerative Diseases Such as Prion and Parkinson’s Disease. Acta Neuropathologica, 125, 795-813. https://doi.org/10.1007/s00401-013-1114-9
|
[148]
|
Fuchigami, T., Yamashita, Y., Kawasaki, M., Ogawa, A., Haratake, M., Atarashi, R, Sano, K., Nakagaki, T., Ubagai, K., Ono, M., Yoshida, S., Nishida, N. and Nakayama, M. (2015) Characterisation of Radioiodinated Flavonoid Derivatives for SPECT Imaging of Cerebral Prion Deposits. Nature—Scientific Reports, 5, 18440.
https://doi.org/10.1038/srep18440
|
[149]
|
Ghaemmaghami, S., Russo, M. and Renslo, A.R. (2014) Success and Challenges in Phenotype Based Lead Discovery for Prion Diseases. Journal of Medicinal Chemistry, 57, 6919-6929. https://doi.org/10.1021/jm5001425
|
[150]
|
Cazaubon, S., Viegas, P. and Couraud, P.-O. (2007) Fonctions de la Protéine Prion PrP. Médecine/Science, 23, 741-745. https://doi.org/10.1051/medsci/20072389741
|
[151]
|
Bannach, O., Birkmann, E., Reinartz, E., Jaeger, K.-E., Langeveld, J.P.M., Rohwer, R.G., Gregori, L., Terry, L.A., Willbold, D. and Riesner, D. (2012) Detection of Prion Protein Particles in Blood Plasma of Scrapie Infected Sheep, PLOS One, 7, e36620. https://doi.org/10.1371/journal.pone.0036620
|
[152]
|
Trevitt, C.R. and Collinge, J. (2006) A Systematic Review of Prion Therapeutics in Experimental Models. Brain, 129, 2241-2265. https://doi.org/10.1093/brain/awl150
|
[153]
|
Honson, N.S., Johnson, R.L., Huang, W., Inglese, J., Austin, C.P. and Kuret, J. (2007) Differentiating Alzheimer Disease-Associated Aggregates with Small Molecules. Neurobiology of Disease, 28, 251-260.
https://doi.org/10.1016/j.nbd.2007.07.018
|
[154]
|
Kamatari, Y.O., Hayano, Y., Yamaguchi, K.-I., Hosokawa-Muto, J. and Kuwata, K. (2013) Characterizing Antiprion Compounds Based on their Binding Properties to Prion Proteins: Implications as Medical Chaperons. Protein Science, 22, 22-34.
https://doi.org/10.1002/pro.2180
|
[155]
|
Matsumura, K. On, M., Yoshimura, M., Kimura, H., Watanabe, H., Okamoto, Y., Ihara, M., Takahashi, R. and Sagi, H. (2013) Synthesis and Biological Evaluation of Novel Styryl Benzimidazole Derivatives as Probes for Imaging of Neurofibrillary Tangles in Alzheimer’s Disease. Bioorganic & Medicinal Chemistry, 21, 3356-3362.
https://doi.org/10.1016/j.bmc.2013.02.054
|
[156]
|
May, B.C.H., Fafarman, A.T., Hong, S.B., Rogers, M., Deady, L.W., Prusiner, S.B. and Cohen, F.E. (2003) Potent Inhibition of Scrapie Prion Replication in Cultured Cells by Bis-Acridines. PNAS, 100, 3416-3421.
https://doi.org/10.1073/pnas.2627988100
|
[157]
|
Bolognesi, M.L., Tran, H.N.A., Staderini, M., Monaco, A., Lopez-Cobenas, A., Bongarzone, S., Biarnes, X., Lopez-Alvarado, P., Cabezas, N., Caramelli, M., Carloni, P., Menendez, J.C. and Legname, G. (2010) Discovery of a Class of Diketopiperazines as Antiprion Compounds. ChemMedChem, 5, 1324-1334.
https://doi.org/10.1002/cmdc.201000133
|
[158]
|
Bosque, P. and Prusiner, S.B. (2000) Cultured Sublines Highly Susceptible to Prion Infection. Journal of Virology, 74, 4377-4386.
https://doi.org/10.1128/JVI.74.9.4377-4386.2000
|
[159]
|
Bongarzone, S., Tran, H.N.A., Cavalli, A., Roberti, M., Carloni, P., Legname, G. and Bolognesi, M.L. (2010) Parallel Synthesis, Evaluation, and Preliminary Structure-Activity Relationship of 2,5-Diamino-1,4-Benzoquinones as a Novel Class of Bivalent Anti-Prion Compound. Journal of Medicinal Chemistry, 53, 8197-8201.
https://doi.org/10.1021/jm100882t
|
[160]
|
Mueller-Gaertner, H.W., Links, J.M., Prince, J.L., Bryan, R.N., McVeigh, E., Leal, J.P., Davazikos, Ch. and Frost, J. (1992) Measurement of Radiotracer Concentration in Brain Gray Matter Using Positron Emission Tomography: MRI-Based Correction for Partial Volume Effects. Journal of Cerebral Blood Flow & Metabolism, 12, 571-583. https://doi.org/10.1038/jcbfm.1992.81
|
[161]
|
Box, K., Comer, J. and Huque, F. (2007) Correlations between PAMPA Permeability and log P. In: Testa, B., Kramer, S.D., Wunderli-Allenspach, H. and Folkers, G., Eds., Pharmacokinetic Profiling in Drug Research—Biological, Physicochemical, and Computational Strategies, 243-257.
|
[162]
|
Bongarzone, S. and Bolognesi, M.L. (2011) The Concept of Privileged Structures in Rational Drug Design: Focus on Acridine and Quinolone Scaffolds in Neurodegenerative and Protozoan Diseases. Expert Opinion on Drug Discovery, 6, 251-268.
https://doi.org/10.1517/17460441.2011.550914
|
[163]
|
Cummings, J.L., Morstorf, T. and Zhon, K. (2014) Alzheimer’s Disease Drug-Development Pipeline: Few Candidates, Frequent Failure. Alzheimer’s Research Therapy, 6, 37, 7 p.
|
[164]
|
Yeo, J.M., Waddell, B., Khan, Z. and Pal, S. (2015) A Systematic and Metaanalysis of 18F-Labelled Amyloid Imaging in Alzheimer’s Disease. Alzheimer’s Dementia, Assessment & Disease Monitoring, 1, 5-13. https://doi.org/10.1016/j.dadm.2014.11.004
|